In addition, the loss of at least one copy of the PTEN gene is associated with a poor worse outcome in HER2-positive breast cancer, although it is not yet clear whether it is predictive of trastuzumab resistance [78,79]. The gene discussed is ERBB2; the disease is breast cancer.